000538 云南白药
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)8.04810.4467.8227.35414.518
总资产报酬率 ROA (%)5.8977.6445.6815.21610.519
投入资产回报率 ROIC (%)6.9848.8746.5436.14112.680

边际利润分析
销售毛利率 (%)29.29526.50626.32327.15027.752
营业利润率 (%)17.95312.3519.2399.58220.805
息税前利润/营业总收入 (%)17.31811.6568.3158.86220.063
净利润/营业总收入 (%)15.59510.5417.7847.69116.831

收益指标分析
经营活动净收益/利润总额(%)87.97083.614130.329133.10163.484
价值变动净收益/利润总额(%)13.12918.7337.353-25.41438.707
营业外收支净额/利润总额(%)-0.009-0.2590.169-0.101-0.160

偿债能力分析
流动比率 (X)2.6412.8512.6313.5783.150
速动比率 (X)2.2072.3452.0422.9192.448
资产负债率 (%)27.54825.80527.74526.5600.306
带息债务/全部投入资本 (%)10.13211.20513.75713.88514.094
股东权益/带息债务 (%)861.228770.454607.468602.950590.858
股东权益/负债合计 (%)262.858287.336260.266275.012225.491
利息保障倍数 (X)-27.329-17.585-8.849-12.480-28.322

营运能力分析
应收账款周转天数 (天)88.31287.70080.28253.14130.742
存货周转天数 (天)77.35290.395109.623131.575173.010